Brexpiprazole (Rexulti): A New Monotherapy for Schizophrenia and Adjunctive Therapy for Major Depressive Disorder

Similar Items

• Spotlight on brexpiprazole and its potential in the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression
  od: Bruijnzeel, Dawn, i dr.
  Izdano: (2016)
• Brexpiprazole: A review of a new treatment option for schizophrenia and major depressive disorder
  od: Diefenderfer, Lauren A., i dr.
  Izdano: (2018)
• The effects of brexpiprazole and aripiprazole on body weight as monotherapy in patients with schizophrenia and as adjunctive treatment in patients with major depressive disorder: an analysis of short-term and long-term studies
  od: Weiss, Catherine, i dr.
  Izdano: (2018)
• Adjunctive brexpiprazole in patients with major depressive disorder and anxiety symptoms: an exploratory study
  od: Davis, Lori L., i dr.
  Izdano: (2016)
• A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Adjunctive Therapy in Adults With Major Depressive Disorder
  od: Hobart, Mary, i dr.
  Izdano: (2019)